Skip to content
Library/For Skin/Melanotan I (Afamelanotide)
FDA Approved (EPP)⚠ Cancer Concern✓ Free to read

Melanotan I (Afamelanotide)

Also called Scenesse

Injected skin-tanning. The only approved use is a rare sun-pain disease, not getting a beach tan.

Updated 03 May 2026Read 4 minBacked by 60 studies
The quick version
What it is
A shot that turns up your skin's tan signal (copies a body hormone)
Is it FDA-approved?
Yes, but only for a rare disease, given as a slow-release implant
How strong is the proof?
Strong for the rare disease. Not studied for cosmetic tanning
How you take it
Approved as an implant under the skin every 2 months. People misuse it as self-shots
Typical result
Darker skin. For the disease, more pain-free time in the sun
Biggest catch
It wakes up the cells that can turn into skin cancer

Any word with a dotted underline is a science word — tap it for a plain-English meaning.

In plain words.

Melanotan I is a . Its real drug name is afamelanotide, sold as Scenesse.

Your body makes a hormone that tells your skin to make a brown color called melanin. Melanin is what gives skin a tan. Melanotan I copies that hormone. So your skin makes more melanin and gets darker.

It is , but only in a narrow way. It is approved for a rare disease called EPP. People with EPP get burning pain from sunlight. Doctors place a tiny implant under the skin every 2 months. That is not the same as someone giving themselves shots to get a tan.

What people use it for.

Doctors use it for the rare sun-pain disease, EPP. It lets those people spend more time in the sun without pain.

Most other people who seek it out want a tan without the sun. They buy the unapproved kind and inject it themselves.

If your goal is sex drive, this is not the one. MT-I is the "cleaner" cousin without that effect. The approved drug for low desire is PT-141.

Does it actually work?

For the rare disease EPP, yes. Two Phase 3 trials showed people got more pain-free time in the sun. That is why it got approved.

For just getting a tan, it does darken your skin. But no real studies checked if doing that, by self-shots, is safe over time. The approved use is small, careful doses under a doctor. Cosmetic tanning is none of those things.

So the tan is real. Whether it is worth the risk has never been tested.

what you’ve probably heard.

The claims floating around online, and how true they actually are.

Melanotan 1 is the clean one, none of the nausea or erections you get from MT-2.

mostly true

It carries fewer stomach and sex-drive side effects than Melanotan II. But fewer side effects is not the same as safe. It still wakes up the exact skin cells that can turn into melanoma.

It's FDA-approved, so injecting it for a tan is fine.

half true

The approved drug, Scenesse, is real, but only as an implant a doctor places for a rare sun-pain disease called EPP. The self-injected tanning version was never approved or tested.

Getting dark from the inside means I'm protected from sunburn.

myth

The extra color does not shield you from sunburn or sun damage. You can still burn and still build the same risk you would lying out.

You can skip the sun completely and still get a tan.

true

It does darken your skin without UV. The tan is real. Whether building it with home shots is safe over time has never been studied.

How you take it.

The approved way is an implant a doctor places under your skin every 2 months. You do not do this part yourself. A skin specialist handles it.

People who buy the research-only kind mix a powder with liquid and inject it under the skin. There is no tested, safe home dose for tanning. Common amounts people talk about are around 10 mg a month, but that is guesswork, not a trial.

We do not suggest the home-shot route at all.

What to watch out for.

The serious stuff

Melanotan I wakes up the cells in your skin that make color. Those same cells are the ones that can turn into melanoma, a dangerous skin cancer. The long-term cancer risk from cosmetic use is unknown.

If you have ever had melanoma, or have lots of odd moles, do not use this.

The common stuff

This one is called the "cleaner" cousin. It has fewer stomach and other side effects than Melanotan II.

If you do use it, get your skin checked by a doctor often. Watch for new or changing moles. And remember: this does not protect you from sunburn or damage. Talk to a real doctor first. We are not your doctor.

Where people get it.

Here are the ways people get it, from safest to riskiest.

  • Brand (Scenesse). A real implant from a specialty pharmacy, with a prescription, for the EPP disease only. Safest, but it costs about $40,000+ a year and is billed to insurance. Not sold for tanning.
  • . There is no real version. Some clinics resell the research kind for $300–$800 and call it compounded. It usually is not.
  • Research-only () or . Cheap, about $50–$120 a month for , or even less from overseas. Sold "for research only," with no promise of what is in the vial. Highest risk.

One big scam: vials labeled "Melanotan I" often ship as Melanotan II instead. That is a different drug with stronger side effects. If your vial made you sick to your stomach or gave you erections, you got MT-II. Ask for a , a lab report showing what is really in the vial.

Our honest take.

Have EPP and a skin specialist offering you Scenesse? That is the one clear yes here. The trials back it, and a doctor handles the dosing for you.

Everyone else is buying it to tan, and that means flipping on the exact cells that can turn into skin cancer with zero safety data behind that use. We would not make that trade for a look you can get from a $12 bottle of self-tanner.

The studies behind this.

We read the research so you don't have to. Here's where the facts on this page come from.

  1. 01Perez-Bootello J, et al. Vitiligo: Pathogenesis and New and Emerging Treatments. International journal of molecular sciences. 2023;24(24). PMID: 38139134.
  2. 02Diotallevi F, et al. Vitiligo, from Pathogenesis to Therapeutic Advances: State of the Art. International journal of molecular sciences. 2023;24(5). PMID: 36902341.
  3. 03 Afamelanotide. 2024. PMID: 38598652.
  4. 04Iwanowski T, et al. Etiopathogenesis and Emerging Methods for Treatment of Vitiligo. International journal of molecular sciences. 2023;24(11). PMID: 37298700.
  5. 05Cong TX, et al. From pathogenesis of acne vulgaris to anti-acne agents. Archives of dermatological research. 2019;311(5):337-349. PMID: 30859308.
  6. 06Ismail IB, et al. Treatment Advances in Vitiligo: An Updated Review. Dermatology practical & conceptual. 2025;15(1). PMID: 40117616.
  7. 07Zubair R, et al. Phototherapy for Vitiligo. Dermatologic clinics. 2020;38(1):55-62. PMID: 31753192.
  8. 08Balwani M, et al. X-Linked Protoporphyria. 2019. PMID: 23409301.
  9. 09Polańska A, et al. Afamelanotide in protoporphyria and other skin diseases: a review. Postepy dermatologii i alergologii. 2024;41(2):149-154. PMID: 38784937.
  10. 10Stölzel U, et al. [Porphyrias-what is verified?]. Der Internist. 2018;59(12):1239-1248. PMID: 30328490.
  11. 11Wensink D, et al. Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert review of clinical pharmacology. 2021;14(2):151-160. PMID: 33507118.
  12. 12Kim ES, et al. Afamelanotide: A Review in Erythropoietic Protoporphyria. American journal of clinical dermatology. 2016;17(2):179-85. PMID: 26979527.
  13. 13Minder EI, et al. Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. Clinical pharmacokinetics. 2017;56(8):815-823. PMID: 28063031.
  14. 14Sweeney P, et al. Targeting the central melanocortin system for the treatment of metabolic disorders. Nature reviews. Endocrinology. 2023;19(9):507-519. PMID: 37365323.
  15. 15Langendonk JG, et al. Afamelanotide for Erythropoietic Protoporphyria. The New England journal of medicine. 2015;373(1):48-59. PMID: 26132941.
  16. 16Wu J, et al. Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications. Journal of drugs in dermatology : JDD. 2021;20(3):290-294. PMID: 33683075.
  17. 17Kluijver LG, et al. The effects of cholecalciferol and afamelanotide on vitamin D levels in erythropoietic protoporphyria: a multicentre cohort study. The British journal of dermatology. 2024;191(3):357-364. PMID: 38634774.
  18. 18Searle T, et al. Systemic photoprotection in 2021. Clinical and experimental dermatology. 2021;46(7):1189-1204. PMID: 33872410.
  19. 19Minder AE, et al. Erythropoietic protoporphyrias: Pathogenesis, diagnosis and management. Liver international : official journal of the International Association for the Study of the Liver. 2025;45(1):e16027. PMID: 39011756.
  20. 20Minder EI. Afamelanotide, an agonistic analog of α-melanocyte-stimulating hormone, in dermal phototoxicity of erythropoietic protoporphyria. Expert opinion on investigational drugs. 2010;19(12):1591-602. PMID: 21073357.
  21. 21Balwani M, et al. Erythropoietic Protoporphyria, Autosomal Recessive. 2017. PMID: 23016163.
  22. 22Minder EI, et al. Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria. Expert review of clinical pharmacology. 2015;8(1):43-53. PMID: 25470471.
  23. 23Zubair R, et al. What's New in Pigmentary Disorders. Dermatologic clinics. 2019;37(2):175-181. PMID: 30850040.
  24. 24Farahnik B, et al. Interventional treatments for Hailey-Hailey disease. Journal of the American Academy of Dermatology. 2017;76(3):551-558.e3. PMID: 27745906.
  25. 25Lane AM, et al. Advances in the management of erythropoietic protoporphyria - role of afamelanotide. The application of clinical genetics. 2016;9:179-189. PMID: 28003770.
  26. 26Biolcati G, et al. Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease. Clinical and experimental dermatology. 2014;39(2):168-75. PMID: 24256215.
  27. 27Minder AE, et al. Afamelanotide Is Associated with Dose-Dependent Protective Effect from Liver Damage Related to Erythropoietic Protoporphyria. Life (Basel, Switzerland). 2023;13(4). PMID: 37109595.
  28. 28Rhodes LE. Vitamin D status in patients with erythropoietic protoporphyria taking the systemic photoprotective agent afamelanotide. The British journal of dermatology. 2024;191(3):317-318. PMID: 38736212.
  29. 29Dawe R. An overview of the cutaneous porphyrias. F1000Research. 2017;6:1906. PMID: 29152226.
  30. 30Leaf RK, et al. Afamelanotide for Treatment of the Protoporphyrias: Impact on Quality of Life and Laboratory Parameters in a US Cohort. Life (Basel, Switzerland). 2024;14(6). PMID: 38929673.
  31. 31Luger TA, et al. An α-MSH analog in erythropoietic protoporphyria. The Journal of investigative dermatology. 2015;135(4):929-931. PMID: 25785940.
  32. 32Resnik SR, et al. Into the Light: Afamelanotide and the Treatment of Erythropoietic Protoporphyria in the United States. Journal of drugs in dermatology : JDD. 2023;22(9):941-949. PMID: 37683058.
  33. 33Wensink D, et al. Objective light exposure measurements and circadian rhythm in patients with erythropoietic protoporphyria: A case-control study. Molecular genetics and metabolism. 2022;135(3):215-220. PMID: 35034844.
  34. 34Habbema L, et al. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. International journal of dermatology. 2017;56(10):975-980. PMID: 28266027.
  35. 35Passeron T. Medical and Maintenance Treatments for Vitiligo. Dermatologic clinics. 2017;35(2):163-170. PMID: 28317526.
  36. 36Searle T, et al. Vitiligo: an update on systemic treatments. Clinical and experimental dermatology. 2021;46(2):248-258. PMID: 33350506.
  37. 37Rodrigues M, et al. Current and emerging treatments for vitiligo. Journal of the American Academy of Dermatology. 2017;77(1):17-29. PMID: 28619557.
  38. 38Chang CL, et al. A gel-forming α-MSH analog promotes lasting melanogenesis. European journal of pharmacology. 2023;958:176008. PMID: 37673364.
  39. 39Jafarzadeh A, et al. A systematic review of case series and clinical trials investigating systemic oral or injectable therapies for the treatment of vitiligo. Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI). 2024;30(3):e13642. PMID: 38454597.
  40. 40Lim HW, et al. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA dermatology. 2015;151(1):42-50. PMID: 25230094.
  41. 41Fabrikant J, et al. A review and update on melanocyte stimulating hormone therapy: afamelanotide. Journal of drugs in dermatology : JDD. 2013;12(7):775-9. PMID: 23884489.
  42. 42de Baat C, et al. [Medicaments and oral healthcare. Hyperpigmentation of oral soft tissues due to afamelanotide]. Nederlands tijdschrift voor tandheelkunde. 2020;127(4):237-243. PMID: 32459219.
  43. 43Kluijver LG, et al. The Impact of Minimal Sunlight Exposure on Bone Health: Insights From a Cohort Study in Erythropoietic Protoporphyria. The Journal of clinical endocrinology and metabolism. 2025;110(6):1633-1646. PMID: 39401412.
  44. 44Homey B, et al. German Cohort Observational Study to Investigate the Short- and Long-Term Safety and Clinical Effectiveness of Afamelanotide 16 mg (SCENESSE) in Patients With Erythropoietic Protoporphyria (EPP). Photodermatology, photoimmunology & photomedicine. 2025;41(2):e13012. PMID: 40082741.
  45. 45Nkwanyana N, et al. Silica-Assisted Solid-Phase Peptide Synthesis (SiPPS). Journal of peptide science : an official publication of the European Peptide Society. 2025;31(9):e70052. PMID: 40817749.
  46. 46Wensink D, et al. Association of Afamelanotide With Improved Outcomes in Patients With Erythropoietic Protoporphyria in Clinical Practice. JAMA dermatology. 2020;156(5):570-575. PMID: 32186677.
  47. 47Toenne M, et al. Erythropoietic protoporphyria in childhood: clinical clues, missed diagnoses and emerging therapy. European journal of pediatrics. 2025;184(9):580. PMID: 40858983.
  48. 48Minder AE, et al. Beyond pigmentation: signs of liver protection during afamelanotide treatment in Swiss patients with erythropoietic protoporphyria, an observational study. Therapeutic advances in rare disease. 2021;2:26330040211065453. PMID: 37181106.
  49. 49Lim HW, et al. Current challenges in photoprotection. Journal of the American Academy of Dermatology. 2017;76(3S1):S91-S99. PMID: 28038886.
  50. 50Bardhan M, et al. Polymorphism of Melanocortin Receptor Genes-Association with Inflammatory Traits and Diseases. Diseases (Basel, Switzerland). 2025;13(9). PMID: 41002740.
  51. 51Lengweiler S, et al. Evaluation of the immunogenicity of the synthetic α-melanocyte-stimulating hormone (α-MSH) analogue afamelanotide ([Nle4-D-Phe7]-α-MSH, Scenesse®) in erythropoietic protoporphyria patients by ELISA detecting both anti-afamelanotide and anti-α-MSH antibodies. Skin pharmacology and physiology. 2015;28(2):103-13. PMID: 25402764.
  52. 52Wensink D, et al. Erythropoietic protoporphyria in the Netherlands: Clinical features, psychosocial impact and the effect of afamelanotide. The Journal of dermatology. 2023;50(4):445-452. PMID: 36579412.
  53. 53O'Reilly M, et al. Erythropoietic protoporphyria and afamelanotide: a patient's perspective. Clinical and experimental dermatology. 2024;49(2):186-187. PMID: 37831089.
  54. 54Al Shaer D, et al. 2019 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals (Basel, Switzerland). 2020;13(3). PMID: 32151051.
  55. 55Biolcati G, et al. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. The British journal of dermatology. 2015;172(6):1601-1612. PMID: 25494545.
  56. 56Erwin AL, et al. Porphyrias in the Age of Targeted Therapies. Diagnostics (Basel, Switzerland). 2021;11(10). PMID: 34679493.
  57. 57Spichty R, et al. A bioassay for the detection of neutralizing antibodies against the α-melanocyte stimulating hormone analog afamelanotide in patients with erythropoietic protoporphyria. Journal of pharmaceutical and biomedical analysis. 2013;75:192-8. PMID: 23277150.
  58. 58Karagaiah P, et al. Emerging drugs for the treatment of vitiligo. Expert opinion on emerging drugs. 2020;25(1):7-24. PMID: 31958256.
  59. 59Stanislaus V, et al. A feasibility and safety study of afamelanotide in acute stroke patients - an open label, proof of concept, phase iia clinical trial. BMC neurology. 2023;23(1):281. PMID: 37496004.
  60. 60Fontanellas A, et al. Current and innovative emerging therapies for porphyrias with hepatic involvement. Journal of hepatology. 2019;71(2):422-433. PMID: 31102718.

We're not your doctor, and this isn't medical advice. It's a plain-English summary of what the research says, so you can have a smarter conversation with someone who is.

Keep up with this stuff

Want the rest of the peptide world, in plain English?

New breakdowns, safety updates, and what's actually worth your money. Free. Unsubscribe in one click.